Details of the Drug Combination

General Information of Drug Combination (ID: DCONSG6)

Drug Combination Name

Eflornithine Bicalutamide

Indication

Disease Entry	Status	REF
Prostate Cancer	Phase 1	[1]

Component Drugs

Eflornithine DMJOQM3

Bicalutamide DMZMSPF

Small molecular drug

2D MOL

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Eflornithine

Disease Entry	ICD 11	Status	REF
African trypanosomiasis	1F51	Approved	[2]
Trypanosomiasis	1D51-1F53	Phase 2	[3]
Colon cancer	2B90.Z	Investigative	[4]
Familial adenomatous polyposis	2B90.Y	Investigative	[4]

Eflornithine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Ornithine decarboxylase (ODC1)	TTUMGNO	DCOR_HUMAN	Inhibitor	[7]
------------------------------------------------------------------------------------

Indication(s) of Bicalutamide

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[5]
Castration-resistant prostate carcinoma	N.A.	Investigative	[6]
Metastatic prostate carcinoma	N.A.	Investigative	[6]

Bicalutamide Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Antagonist	[13]
------------------------------------------------------------------------------------

Bicalutamide Interacts with 2 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[14]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[14]
------------------------------------------------------------------------------------

Bicalutamide Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[15]
------------------------------------------------------------------------------------

Bicalutamide Interacts with 127 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Decreases Response To Substance	[16]
Telomerase reverse transcriptase (TERT)	OT085VVA	TERT_HUMAN	Decreases Expression	[8]
Neuropilin-1 (NRP1)	OTCGULYV	NRP1_HUMAN	Decreases Expression	[8]
Calmegin (CLGN)	OTEWVFQV	CLGN_HUMAN	Increases Expression	[8]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[8]
Protein regulator of cytokinesis 1 (PRC1)	OTHD0XS0	PRC1_HUMAN	Decreases Expression	[8]
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B)	OT8KME51	BUB1B_HUMAN	Decreases Expression	[8]
H/ACA ribonucleoprotein complex subunit DKC1 (DKC1)	OTX7DJR6	DKC1_HUMAN	Decreases Expression	[8]
Nebulette (NEBL)	OT2WH1NC	NEBL_HUMAN	Increases Expression	[8]
Kinesin-like protein KIF20A (KIF20A)	OTXOQHE0	KI20A_HUMAN	Decreases Expression	[8]
Anterior gradient protein 2 homolog (AGR2)	OTRRZT7W	AGR2_HUMAN	Increases Expression	[8]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Decreases Expression	[8]
Pro-glucagon (GCG)	OTXU08VF	GLUC_HUMAN	Decreases Expression	[8]
Thymidine kinase, cytosolic (TK1)	OTY5JFM1	KITH_HUMAN	Decreases Expression	[8]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[8]
Cholinesterase (BCHE)	OTOH3WQ9	CHLE_HUMAN	Decreases Expression	[8]
Cyclin-dependent kinase 1 (CDK1)	OTW1SC2N	CDK1_HUMAN	Decreases Expression	[8]
Prostate-specific antigen (KLK3)	OTFGSBFJ	KLK3_HUMAN	Decreases Expression	[8]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Increases Expression	[8]
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1)	OTXOQDSG	IFIT1_HUMAN	Decreases Expression	[8]
Proliferating cell nuclear antigen (PCNA)	OTHZ1RIA	PCNA_HUMAN	Decreases Expression	[8]
Prostatic acid phosphatase (ACP3)	OTSIM0YG	PPAP_HUMAN	Decreases Expression	[8]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Increases Expression	[8]
C-X-C motif chemokine 3 (CXCL3)	OTSL94KH	CXCL3_HUMAN	Increases Expression	[8]
Kallikrein-2 (KLK2)	OT9RE37R	KLK2_HUMAN	Decreases Expression	[8]
Lamin-B1 (LMNB1)	OT100T3P	LMNB1_HUMAN	Decreases Expression	[8]
Midkine (MDK)	OTF24HKC	MK_HUMAN	Increases Expression	[8]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Increases Expression	[8]
Protein S100-P (S100P)	OTJCXNJG	S100P_HUMAN	Increases Expression	[8]
Ribonucleoside-diphosphate reductase subunit M2 (RRM2)	OTOB6J6R	RIR2_HUMAN	Decreases Expression	[8]
Stress-induced-phosphoprotein 1 (STIP1)	OT7TXLOX	STIP1_HUMAN	Decreases Expression	[8]
Cyclin-dependent kinases regulatory subunit 2 (CKS2)	OTPTMHIV	CKS2_HUMAN	Decreases Expression	[8]
Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (MAN1A1)	OT6LIGJP	MA1A1_HUMAN	Increases Expression	[8]
Glypican-1 (GPC1)	OTQKRSSV	GPC1_HUMAN	Decreases Expression	[8]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[8]
Cyclin-dependent kinase 4 inhibitor C (CDKN2C)	OTCLOV90	CDN2C_HUMAN	Decreases Expression	[8]
Ran-specific GTPase-activating protein (RANBP1)	OTQE226K	RANG_HUMAN	Decreases Expression	[8]
Proliferation marker protein Ki-67 (MKI67)	OTA8N1QI	KI67_HUMAN	Decreases Expression	[8]
DNA replication licensing factor MCM2 (MCM2)	OTGGORIQ	MCM2_HUMAN	Decreases Expression	[8]
Aldehyde dehydrogenase family 3 member A2 (ALDH3A2)	OT714BUO	AL3A2_HUMAN	Increases Expression	[8]
Serine/threonine-protein kinase Nek2 (NEK2)	OT1H27HO	NEK2_HUMAN	Decreases Expression	[8]
Thyroxine 5-deiodinase (DIO3)	OTNTITOT	IOD3_HUMAN	Increases Expression	[8]
Neutrophil gelatinase-associated lipocalin (LCN2)	OTSB42BR	NGAL_HUMAN	Increases Expression	[8]
Cell division cycle protein 20 homolog (CDC20)	OTCOEZRV	CDC20_HUMAN	Decreases Expression	[8]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1)	OTXNGZCG	MD2L1_HUMAN	Decreases Expression	[8]
Sequestosome-1 (SQSTM1)	OTGY5D5J	SQSTM_HUMAN	Increases Expression	[8]
Transmembrane glycoprotein NMB (GPNMB)	OTB7KQKV	GPNMB_HUMAN	Increases Expression	[8]
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase (EBP)	OTSMGKXQ	EBP_HUMAN	Decreases Expression	[8]
Quinone oxidoreductase PIG3 (TP53I3)	OTSCM68G	QORX_HUMAN	Increases Expression	[8]
Retinoic acid-induced protein 3 (GPRC5A)	OTPOCWR7	RAI3_HUMAN	Decreases Expression	[8]
Fibroblast growth factor 13 (FGF13)	OTHNNVSG	FGF13_HUMAN	Increases Expression	[8]
Lymphokine-activated killer T-cell-originated protein kinase (PBK)	OT5Z27TW	TOPK_HUMAN	Decreases Expression	[8]
Tribbles homolog 3 (TRIB3)	OTG5OS7X	TRIB3_HUMAN	Increases Expression	[8]
BRCA1-associated RING domain protein 1 (BARD1)	OTTC0Z9Y	BARD1_HUMAN	Decreases Expression	[8]
Homeobox protein Nkx-3.1 (NKX3-1)	OT0DO6ZU	NKX31_HUMAN	Decreases Expression	[8]
GTP-binding protein 2 (GTPBP2)	OTOJ1KUA	GTPB2_HUMAN	Increases Expression	[8]
Nucleolar and spindle-associated protein 1 (NUSAP1)	OT85HIJ5	NUSAP_HUMAN	Decreases Expression	[8]
Peroxisomal trans-2-enoyl-CoA reductase (PECR)	OT5MS8EM	PECR_HUMAN	Increases Expression	[8]
Protein Niban 1 (NIBAN1)	OTYOLI12	NIBA1_HUMAN	Increases Expression	[8]
Rac GTPase-activating protein 1 (RACGAP1)	OTQE8IEH	RGAP1_HUMAN	Decreases Expression	[8]
E3 ubiquitin-protein ligase CCNB1IP1 (CCNB1IP1)	OTOTVMC8	CIP1_HUMAN	Increases Expression	[8]
Peptidyl-prolyl cis-trans isomerase FKBP11 (FKBP11)	OTY2GC67	FKB11_HUMAN	Increases Expression	[8]
DnaJ homolog subfamily B member 9 (DNAJB9)	OT38EQT6	DNJB9_HUMAN	Increases Expression	[8]
Alpha-methylacyl-CoA racemase (AMACR)	OTUU22PK	AMACR_HUMAN	Decreases Expression	[8]
E3 ISG15--protein ligase HERC5 (HERC5)	OTZ5PR39	HERC5_HUMAN	Increases Expression	[8]
Cell cycle progression protein 1 (CCPG1)	OT0IHDKL	CCPG1_HUMAN	Increases Expression	[8]
Targeting protein for Xklp2 (TPX2)	OTWLJYH0	TPX2_HUMAN	Decreases Expression	[8]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Increases Expression	[8]
Lysosome-associated membrane glycoprotein 3 (LAMP3)	OTN0XL3W	LAMP3_HUMAN	Increases Expression	[8]
Hypoxia up-regulated protein 1 (HYOU1)	OTBGBSOV	HYOU1_HUMAN	Increases Expression	[8]
Electrogenic sodium bicarbonate cotransporter 1 (SLC4A4)	OT727K92	S4A4_HUMAN	Decreases Expression	[8]
Kunitz-type protease inhibitor 2 (SPINT2)	OTQV7BKQ	SPIT2_HUMAN	Increases Expression	[9]
Neprilysin (MME)	OT5Q39P8	NEP_HUMAN	Increases Expression	[9]
Retinoic acid receptor beta (RARB)	OT367U3E	RARB_HUMAN	Increases Expression	[9]
S-adenosylmethionine decarboxylase proenzyme (AMD1)	OTKAGZY3	DCAM_HUMAN	Increases Expression	[9]
CD9 antigen (CD9)	OT2184XU	CD9_HUMAN	Increases Expression	[9]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1)	OTB06ESI	ACSL1_HUMAN	Increases Expression	[9]
Histone H2B type 1-B (H2BC3)	OT1BLFJO	H2B1B_HUMAN	Increases Expression	[9]
Lipopolysaccharide-responsive and beige-like anchor protein (LRBA)	OTOUZN9G	LRBA_HUMAN	Increases Expression	[9]
Synaptosomal-associated protein 25 (SNAP25)	OTUIQ81Q	SNP25_HUMAN	Increases Expression	[9]
Sorbitol dehydrogenase (SORD)	OTC44CR6	DHSO_HUMAN	Increases Expression	[9]
Rod outer segment membrane protein 1 (ROM1)	OTE7H0YV	ROM1_HUMAN	Increases Expression	[9]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)	OT4SO7J4	BNIP3_HUMAN	Increases Expression	[9]
Cyclin-G2 (CCNG2)	OTII38K2	CCNG2_HUMAN	Increases Expression	[9]
Unconventional myosin-VI (MYO6)	OTJQYRC7	MYO6_HUMAN	Increases Expression	[9]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Increases Phosphorylation	[10]
Arginase-1 (ARG1)	OTHZITAM	ARGI1_HUMAN	Decreases Expression	[17]
Arginase-2, mitochondrial (ARG2)	OTCPI0E8	ARGI2_HUMAN	Increases Expression	[17]
Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 (ASAP2)	OTGEXULW	ASAP2_HUMAN	Increases Expression	[11]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[18]
Low-density lipoprotein receptor (LDLR)	OTH559LU	LDLR_HUMAN	Affects Localization	[19]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Decreases Activity	[20]
Insulin-like growth factor I (IGF1)	OTIIZR61	IGF1_HUMAN	Increases Expression	[21]
Beta-2 adrenergic receptor (ADRB2)	OTSDOX4Q	ADRB2_HUMAN	Decreases Expression	[22]
Beta-microseminoprotein (MSMB)	OTYORAJC	MSMB_HUMAN	Decreases Expression	[23]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Increases Expression	[24]
Prolactin-inducible protein (PIP)	OTH719AH	PIP_HUMAN	Decreases Expression	[25]
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Affects Localization	[19]
Lysosome-associated membrane glycoprotein 2 (LAMP2)	OTLUGEJC	LAMP2_HUMAN	Increases Expression	[11]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Decreases Expression	[26]
Insulin-like growth factor-binding protein 3 (IGFBP3)	OTIX63TX	IBP3_HUMAN	Decreases Expression	[21]
Insulin-like growth factor-binding protein 2 (IGFBP2)	OTG1P60E	IBP2_HUMAN	Increases Expression	[21]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Decreases Expression	[26]
Phosphatidylcholine translocator ABCB4 (ABCB4)	OTE6PY83	MDR3_HUMAN	Decreases Activity	[18]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Decreases Expression	[27]
Retinoic acid receptor RXR-beta (RXRB)	OTNPDXG2	RXRB_HUMAN	Decreases Expression	[24]
Coatomer subunit beta' (COPB2)	OT82JIGC	COPB2_HUMAN	Increases Expression	[11]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Increases Expression	[24]
ATP synthase subunit e, mitochondrial (ATP5ME)	OTADVEE2	ATP5I_HUMAN	Increases Expression	[11]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)	OTOWDUNT	PTEN_HUMAN	Increases Activity	[28]
26S proteasome complex subunit SEM1 (SEM1)	OTASLBM1	SEM1_HUMAN	Increases Expression	[11]
Thymosin beta-4 (TMSB4X)	OT9HPLP3	TYB4_HUMAN	Increases Expression	[29]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[27]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[27]
Peptidyl-prolyl cis-trans isomerase FKBP5 (FKBP5)	OT404F9K	FKBP5_HUMAN	Decreases Expression	[27]
Angio-associated migratory cell protein (AAMP)	OTZXBSS4	AAMP_HUMAN	Increases Expression	[11]
Translocating chain-associated membrane protein 1 (TRAM1)	OT3I0H8E	TRAM1_HUMAN	Increases Expression	[11]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Decreases Activity	[30]
Phosphatidate cytidylyltransferase, mitochondrial (TAMM41)	OTXBJ9W5	TAM41_HUMAN	Increases Expression	[11]
Cell division control protein 6 homolog (CDC6)	OTX93FE7	CDC6_HUMAN	Decreases Expression	[26]
Cytochrome c oxidase assembly factor 1 homolog (COA1)	OTHSX40F	COA1_HUMAN	Increases Expression	[11]
Ankyrin repeat and IBR domain-containing protein 1 (ANKIB1)	OTGKB7Y2	AKIB1_HUMAN	Increases Expression	[11]
Methyl-CpG-binding domain protein 2 (MBD2)	OTUQPP0R	MBD2_HUMAN	Increases Expression	[11]
Beta-1,4-galactosyltransferase 6 (B4GALT6)	OTBM8F2U	B4GT6_HUMAN	Increases Expression	[11]
BTB/POZ domain-containing protein 3 (BTBD3)	OTZ607YT	BTBD3_HUMAN	Increases Expression	[11]
Proliferation-associated protein 2G4 (PA2G4)	OT7IG7HT	PA2G4_HUMAN	Increases Response To Substance	[31]
Neurotensin/neuromedin N (NTS)	OTPGDNQS	NEUT_HUMAN	Decreases Response To Substance	[32]
------------------------------------------------------------------------------------


⏷ Show the Full List of 127 DOT(s)

References

1	ClinicalTrials.gov (NCT00086736) Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5176).
3	ClinicalTrials.gov (NCT01636128) Urinary Biomarker Study With Sulindac and Difluoromethylornithine. U.S. National Institutes of Health.
4	Eflornithine FDA Label
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2863).
6	Bicalutamide FDA Label
7	Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43.
8	Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol. 2005 Jan;57(1):83-92.
9	Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model. BMC Urol. 2005 Mar 24;5:5.
10	Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene. 2007 Dec 6;26(55):7611-9.
11	Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen. Cancer Genet Cytogenet. 2006 Apr 15;166(2):130-8. doi: 10.1016/j.cancergencyto.2005.09.012.
12	Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells. Cancer Res. 2009 Apr 1;69(7):3140-7. doi: 10.1158/0008-5472.CAN-08-3738. Epub 2009 Mar 24.
13	Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
14	Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11.
15	Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-78.
16	Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
17	Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. PLoS One. 2010 Aug 11;5(8):e12107.
18	Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
19	Labeling and identification of LNCaP cell surface proteins: a pilot study. Prostate. 2007 Jun 15;67(9):943-54. doi: 10.1002/pros.20580.
20	Structure-based virtual screening of CYP1A1 inhibitors: towards rapid tier-one assessment of potential developmental toxicants. Arch Toxicol. 2021 Sep;95(9):3031-3048. doi: 10.1007/s00204-021-03111-2. Epub 2021 Jun 28.
21	DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab. 2006 May;290(5):E952-60. doi: 10.1152/ajpendo.00451.2005. Epub 2005 Dec 20.
22	Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.
23	In silico and in vitro assessment of androgen receptor antagonists. Comput Biol Chem. 2021 Jun;92:107490. doi: 10.1016/j.compbiolchem.2021.107490. Epub 2021 Apr 23.
24	Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide. Neoplasma. 2001;48(5):419-24.
25	Regulation of GCDFP-15 expression in human mammary cancer cells. Int J Mol Med. 1999 Aug;4(2):135-40. doi: 10.3892/ijmm.4.2.135.
26	Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase. J Cell Physiol. 2005 Aug;204(2):381-7. doi: 10.1002/jcp.20422.
27	Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12.
28	Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells. Prostate. 2006 Jul 1;66(10):1114-23. doi: 10.1002/pros.20447.
29	Downregulation of thymosin beta4 expression by androgen in prostate cancer LNCaP cells. J Androl. 2008 Mar-Apr;29(2):207-12. doi: 10.2164/jandrol.107.003608. Epub 2007 Oct 3.
30	Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
31	The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9890-5. doi: 10.1073/pnas.0503829102. Epub 2005 Jun 30.
32	A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate. 2007 Feb 1;67(2):190-202. doi: 10.1002/pros.20518.